The Role of Epigenetics in Cardiovascular Disease: Providing Insights into Disease Mechanisms and Evaluating Therapeutic Potential for Future Treatment Strategies
Cardiovascular diseases (CVDs) represent enormous economic and healthcare concerns, prompting the development of preventative and treatment strategies. Research is vital in understanding the core mechanisms of many illnesses, such as epigenetics, and concentrating on primary prevention. Early invest...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-07-01
|
| Series: | APIK Journal of Internal Medicine |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ajim.ajim_46_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Cardiovascular diseases (CVDs) represent enormous economic and healthcare concerns, prompting the development of preventative and treatment strategies. Research is vital in understanding the core mechanisms of many illnesses, such as epigenetics, and concentrating on primary prevention. Early investigations have established a relationship between DNA methylation, histone changes, and RNA-based processes, leading to cardiovascular illnesses such as atherosclerosis, cardiac hypertrophy, myocardial infarction, and heart failure (HF). Currently, various pharmaceutical medications created from these research initiatives are undergoing clinical testing. However, no epigenetically active medicines targeting histone acetylation and methylation have been tested in clinical trials for CVDs. Additional investigation is required to understand the intricate link between epigenetic regulation and CVD drug development. RNA therapies are being developed, and the use of microRNAs and their targets as diagnostic and prognostic indicators holds considerable potential. Further study is required to increase our knowledge of the role of long noncoding RNAs (lncRNAs) in modifying gene expression anomalies causing HF. Innovative therapeutic options that prevent HF focusing on interfering with lncRNA pathways may be devised. Research and testing findings offer the potential to strengthen the therapeutic arsenal. This article gives a summary of the available understanding of epigenetic processes, substances relevant to cardiovascular illnesses, and approaches for their prevention and therapy. |
|---|---|
| ISSN: | 2666-1802 2666-1810 |